Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2026)

Crinetics Pharmaceuticals has reported Accounts Payables for 10 years, with the latest figure at $37.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 280.89% year-over-year to $37.5 million; the trailing twelve-month figure through Mar 2026 stood at $37.5 million (up 280.89% YoY), and the FY2025 full-year result was $41.8 million, up 94.56% from the prior year.
• Accounts Payables for Q1 2026 stood at $37.5 million, down from $41.8 million in the prior quarter.
• The five-year high for Accounts Payables was $41.8 million in Q4 2025, with the low at $5.9 million in Q1 2023.
• Average Accounts Payables over 5 years is $19.5 million, with a median of $18.3 million recorded in 2024.
• Year-over-year, Accounts Payables jumped 386.56% in 2024 and slumped 65.69% in 2025.
• Tracing CRNX's Accounts Payables over 5 years: stood at $6.9 million in 2022, then decreased by 4.87% to $6.5 million in 2023, then jumped by 227.87% to $21.5 million in 2024, then soared by 94.56% to $41.8 million in 2025, then dropped by 10.25% to $37.5 million in 2026.
• The last three Accounts Payables figures came in at $37.5 million (Q1 2026), $41.8 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.

Peer Comparison